Taken together, these data suggest that PD-1 blockade, either by genetic knockout or antibody treatment, promotes IMQ-induced psoriasis-like dermatitis, and that PD-1 blockade in the context of cancer does not increase the severity of dermatitis. Here, PDCD1 is linked to skin disorder.